muscle loss with semaglutide Trims Volume but Physical Function Not Lost Tirzepatide vs. Semaglutide: Which GLP-1
Description
Moscarello, J
The study found that semaglutide was associated with a higher incidence of gastrointestinal adverse events (62%) compared to placebo (42%), with a higher rate of cholelithiasis (4% versus 0%)
Yes, especially in the early stages
However, these benefits were based on clinical endpoints and did not include direct measures of renal fibrosis, such as histology or fibrosis-specific biomarkers [55]
This process typically takes several months to complete after MHRA approval
